{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:26:08Z","timestamp":1762608368648},"reference-count":42,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"<jats:p>Neurofibromatosis type 1, the most common phakomatoses, can present with a host of signs and symptoms, usually involving the skin and the peripheral nervous system. It is characterized by a mutation in the neurofibromatosis type 1 gene on chromosome 17q11.2 that codes for the protein neurofibromin. Neurofibromin acts as a tumor suppressor gene by inhibiting rat sarcoma (Ras) activity and its deficiency leads to increased Ras activity, cellular proliferation and tumor formation. This review was conducted to analyze the various targeted therapies at the genetic and molecular level employed to manage the tumors and other clinical presentations associated with neurofibromatosis type 1. Twenty-eight studies of treatment modalities for the conditions associated with neurofibromatosis and which involved either targeted gene therapy or molecular level therapies, including the latest advances, were included in this review. Mitogen-activated protein kinase kinase inhibition, mammalian target of Rapamycin inhibition and Tyrosine kinase inhibition, represent some of the newer treatment options in this category. Although there are a number of trials for providing therapeutic options at the genetic and molecular level for the various physical and psychological morbidities associated with neurofibromatosis type 1, most of them are in the preclinical stage. Increased clinical trials of the molecules and gene therapies could significantly help in managing the various chronic and sometimes, life-threatening conditions associated with neurofibromatosis 1 and these will probably represent the preferred treatment direction of the future.<\/jats:p>","DOI":"10.25259\/ijdvl_6_2020","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T11:51:10Z","timestamp":1627559470000},"page":"1-10","update-policy":"http:\/\/dx.doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeted genetic and molecular therapies in neurofibromatosis \u2013 A review of present therapeutic options and a glimpse into the future"],"prefix":"10.25259","volume":"88","author":[{"given":"Kaberi","family":"Feroze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feroze","family":"Kaliyadan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, College of Medicine, King Faisal University, Hofuf, Saudi Arabia,"},{"name":"Department of Dermatology, Sree Narayana Institute of Medical Sciences, Chalakka, Kerala, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2021,7,29]]},"reference":[{"key":"10.25259\/IJDVL_6_2020\/ref-1","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/2047-783X-14-3-102","article-title":"Neurofibromatosis","volume":"14","author":"Gerber","year":"2009","journal-title":"Eur J Med Res"},{"key":"10.25259\/IJDVL_6_2020\/ref-2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ebiom.2016.04.036","article-title":"Neurofibromatosis Type 1 molecular diagnosis: The RNA point of view","volume":"7","author":"Pasmant","year":"2016","journal-title":"EBioMedicine"},{"key":"10.25259\/IJDVL_6_2020\/ref-3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/14728222.2018.1465931","article-title":"Emerging therapeutic targets for neurofibromatosis Type 1","volume":"22","author":"Walker","year":"2018","journal-title":"Expert Opin Ther Targets"},{"key":"10.25259\/IJDVL_6_2020\/ref-4","first-page":"34","article-title":"Neurofibromatosis von recklinghausen typ 1 (NF1)-klinick\u00fd obraz a molekul\u00e1rne-genetick\u00e1 diagnostika [Neurofibromatosis von Recklinghausen Type 1 (NF1)-clinical picture and molecular-genetics diagnostic]","volume":"51","author":"Petr\u00e1k","year":"2015","journal-title":"Cesk Patol"},{"key":"10.25259\/IJDVL_6_2020\/ref-5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1542\/peds.2007-3204","article-title":"Neurofibromatosis Type 1 revisited","volume":"123","author":"Williams","year":"2009","journal-title":"Pediatrics"},{"key":"10.25259\/IJDVL_6_2020\/ref-6","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/neuonc\/nov200","article-title":"Therapeutic advances for the tumors associated with neurofibromatosis Type 1, Type 2 and schwannomatosis","volume":"18","author":"Blakeley","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.25259\/IJDVL_6_2020\/ref-7","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","article-title":"Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer","volume":"26","author":"Roberts","year":"2007","journal-title":"Oncogene"},{"key":"10.25259\/IJDVL_6_2020\/ref-8","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s12640-019-0003-y","article-title":"The role of PI3K\/Akt and ERK in neurodegenerative disorders","volume":"35","author":"Rai","year":"2019","journal-title":"Neurotox Res"},{"key":"10.25259\/IJDVL_6_2020\/ref-9","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.7150\/ijbs.27173","article-title":"The PI3K\/AKT pathway in obesity and Type 2 diabetes","volume":"14","author":"Huang","year":"2018","journal-title":"Int J Biol Sci"},{"key":"10.25259\/IJDVL_6_2020\/ref-10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13578-020-00416-0","article-title":"Roles of the PI3K\/AKT\/mTOR signalling pathways in neurodegenerative diseases and tumours","volume":"10","author":"Xu","year":"2020","journal-title":"Cell Biosci"},{"key":"10.25259\/IJDVL_6_2020\/ref-11","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1158\/1078-0432.CCR-13-2576","article-title":"Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs","volume":"20","author":"Patwardhan","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.25259\/IJDVL_6_2020\/ref-12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jmg.39.5.311","article-title":"Malignant peripheral nerve sheath tumours in neurofibromatosis 1","volume":"39","author":"Evans","year":"2002","journal-title":"J Med Genet"},{"key":"10.25259\/IJDVL_6_2020\/ref-13","doi-asserted-by":"publisher","first-page":"5533","DOI":"10.1158\/1078-0432.CCR-06-0792","article-title":"The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis Type 1","volume":"12","author":"Barkan","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.25259\/IJDVL_6_2020\/ref-14","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1172\/JCI60578","article-title":"MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors","volume":"123","author":"Jessen","year":"2013","journal-title":"J Clin Invest"},{"key":"10.25259\/IJDVL_6_2020\/ref-15","doi-asserted-by":"publisher","first-page":"e0187700","DOI":"10.1371\/journal.pone.0187700","article-title":"MEK inhibitors enhance therapeutic response towards ATRA in NF1 associated malignant peripheral nerve sheath tumors (MPNST) in vitro","volume":"12","author":"Fischer-Huchzermeyer","year":"2017","journal-title":"PLoS One"},{"key":"10.25259\/IJDVL_6_2020\/ref-16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/S0140-6736(08)61277-5","article-title":"Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: A 1-year follow-up study","volume":"372","author":"Lantieri","year":"2008","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_6_2020\/ref-17","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.cell.2008.08.041","article-title":"Nf1-dependent tumors require a microenvironment containing Nf1+\/--and c-kit-dependent bone marrow","volume":"135","author":"Yang","year":"2008","journal-title":"Cell"},{"key":"10.25259\/IJDVL_6_2020\/ref-18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11060-009-0049-4","article-title":"Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model","volume":"98","author":"Demestre","year":"2010","journal-title":"J Neurooncol"},{"key":"10.25259\/IJDVL_6_2020\/ref-19","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/S1470-2045(12)70414-X","article-title":"Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis Type 1: A phase 2 trial","volume":"13","author":"Robertson","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.25259\/IJDVL_6_2020\/ref-20","doi-asserted-by":"publisher","first-page":"e107760","DOI":"10.1371\/journal.pone.0107760","article-title":"Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo","volume":"9","author":"Wei","year":"2014","journal-title":"PLoS One"},{"key":"10.25259\/IJDVL_6_2020\/ref-21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/neuonc\/now158","article-title":"Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis Type 1 and unresectable plexiform neurofibromas","volume":"19","author":"Jakacki","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.25259\/IJDVL_6_2020\/ref-22","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/pbc.25041","article-title":"Phase II trial of pirfenidone in children and young adults with neurofibromatosis Type 1 and progressive plexiform neurofibromas","volume":"61","author":"Widemann","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.25259\/IJDVL_6_2020\/ref-23","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1212\/01.wnl.0000243231.12248.67","article-title":"Phase II trial of pirfenidone in adults with neurofibromatosis Type 1","volume":"67","author":"Babovic-Vuksanovic","year":"2006","journal-title":"Neurology"},{"key":"10.25259\/IJDVL_6_2020\/ref-24","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_6_2020\/ref-25","article-title":"FDA Approves Selumetinib for Neurofibromatosis Type 1 with Symptomatic","year":"2021","journal-title":"Inoperable Plexiform Neurofibromas"},{"key":"10.25259\/IJDVL_6_2020\/ref-26","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1002\/pbc.25546","article-title":"Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of neurofibromatosis Type 1","volume":"62","author":"Jousma","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.25259\/IJDVL_6_2020\/ref-27","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/neuonc\/nou235","article-title":"Sirolimus for progressive neurofibromatosis Type 1-associated plexiform neurofibromas: A neurofibromatosis clinical trials consortium phase II study","volume":"17","author":"Weiss","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.25259\/IJDVL_6_2020\/ref-28","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1093\/neuonc\/nou004","article-title":"Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis Type 1 and progressive plexiform neurofibromas","volume":"16","author":"Widemann","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.25259\/IJDVL_6_2020\/ref-29","doi-asserted-by":"publisher","first-page":"6069","DOI":"10.1038\/s41598-018-24484-y","article-title":"Tranilast inhibits the expression of genes related to epithelialmesenchymal transition and angiogenesis in neurofibromin-deficient cells","volume":"8","author":"Harigai","year":"2018","journal-title":"Sci Rep"},{"key":"10.25259\/IJDVL_6_2020\/ref-30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11060-013-1295-z","article-title":"Efficacy and selectivity of nilotinib on NF1-associated tumors in vitro","volume":"116","author":"Jiang","year":"2014","journal-title":"J Neurooncol"},{"key":"10.25259\/IJDVL_6_2020\/ref-31","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1158\/1078-0432.CCR-12-1067","article-title":"Prognostic significance of AKT\/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors","volume":"19","author":"Endo","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.25259\/IJDVL_6_2020\/ref-32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.celrep.2013.12.001","article-title":"BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through BIM induction","volume":"6","author":"Patel","year":"2014","journal-title":"Cell Rep"},{"key":"10.25259\/IJDVL_6_2020\/ref-33","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1158\/0008-5472.CAN-13-1934","article-title":"Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors","volume":"74","author":"Chau","year":"2014","journal-title":"Cancer Res"},{"key":"10.25259\/IJDVL_6_2020\/ref-34","doi-asserted-by":"publisher","first-page":"35753","DOI":"10.18632\/oncotarget.7099","article-title":"Dual mTORC1\/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells","volume":"7","author":"Varin","year":"2016","journal-title":"Oncotarget"},{"key":"10.25259\/IJDVL_6_2020\/ref-35","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.18632\/oncotarget.1609","article-title":"Co-targeting the MAPK and PI3K\/AKT\/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity","volume":"5","author":"Watson","year":"2014","journal-title":"Oncotarget"},{"key":"10.25259\/IJDVL_6_2020\/ref-36","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.gene.2015.04.001","article-title":"Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors","volume":"565","author":"Deyle","year":"2015","journal-title":"Gene"},{"key":"10.25259\/IJDVL_6_2020\/ref-37","doi-asserted-by":"publisher","first-page":"7240","DOI":"10.1074\/jbc.M009202200","article-title":"Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1-\/-cells","volume":"276","author":"Hiatt","year":"2001","journal-title":"J Biol Chem"},{"key":"10.25259\/IJDVL_6_2020\/ref-38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.bone.2017.02.012","article-title":"Pharmacologically targeting beta-catenin for NF1 associated deficiencies in fracture repair","volume":"98","author":"Baht","year":"2017","journal-title":"Bone"},{"key":"10.25259\/IJDVL_6_2020\/ref-39","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.bone.2011.09.043","article-title":"JNK inhibitors increase osteogenesis in Nf1-deficient cells","volume":"49","author":"Sullivan","year":"2011","journal-title":"Bone"},{"key":"10.25259\/IJDVL_6_2020\/ref-40","doi-asserted-by":"publisher","first-page":"10358","DOI":"10.1158\/0008-5472.CAN-08-2506","article-title":"Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation","volume":"68","author":"Daginakatte","year":"2008","journal-title":"Cancer Res"},{"key":"10.25259\/IJDVL_6_2020\/ref-41","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1097\/j.pain.0000000000001002","article-title":"CRISPR\/ Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis Type 1-related pain that is reversed by (S)-Lacosamide","volume":"158","author":"Moutal","year":"2017","journal-title":"Pain"},{"key":"10.25259\/IJDVL_6_2020\/ref-42","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/mp.2015.48","article-title":"HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis Type 1","volume":"20","author":"Omrani","year":"2015","journal-title":"Mol Psychiatry"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/targeted-genetic-and-molecular-therapies-in-neurofibromatosis-a-review-of-present-therapeutic-options-and-a-glimpse-into-the-future\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/targeted-genetic-and-molecular-therapies-in-neurofibromatosis-a-review-of-present-therapeutic-options-and-a-glimpse-into-the-future\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T11:57:49Z","timestamp":1679313469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/targeted-genetic-and-molecular-therapies-in-neurofibromatosis-a-review-of-present-therapeutic-options-and-a-glimpse-into-the-future\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,29]]},"references-count":42,"alternative-id":["10.25259\/IJDVL_6_2020"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_6_2020","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,29]]},"article-number":"1"}}